Listed

BridgeBio Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 17:07 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$8.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$8.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2020-07-01 to 2020-09-30$92.0mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$246.9mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-07-01 to 2020-09-30−$119.9mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30−$347.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$10.9mus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$25.7mus-gaap:InterestExpense
Net income3 months2020-07-01 to 2020-09-30−$130.2mus-gaap:ProfitLoss
Net income9 months2020-01-01 to 2020-09-30−$370.5mus-gaap:ProfitLoss
Diluted EPS3 months2020-07-01 to 2020-09-30−$0.98us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30−$2.79us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2020-01-01 to 2020-09-30−$303.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$5.4mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2020-01-01 to 2020-09-30$75.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-09-30$367.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$745.4mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$787.7mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$75.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$569.3mus-gaap:Liabilities
Long-term debtAt period end2020-09-30$93.4mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-09-30$163.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-051460. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.